摘要:
The present invention discloses a method for directly constructing highly optically active tetrasubstituted allenic acid compounds, i.e., a one-step process for directly constructing highly optically active axially chiral tetrasubstituted allenic acid compounds by using tertiary propargyl alcohol, carbon monoxide and water as reactants in an organic solvent in the presence of palladium catalyst, chiral diphosphine ligand, monophosphine ligand and organic phosphoric acid. The method of the present invention has the following advantages: operations are simple, raw materials and reagents are readily available, the reaction conditions are mild, the substrate has high universality, the functional group has good compatibility, and the reaction has high enantioselectivity (90%∼> 99% ee). The highly optically active allenic acid compounds obtained by the present invention can be used as an important intermediate to construct γ-butyrolactone compounds containing tetrasubstituted chiral quaternary carbon centers, tetrasubstituted allenic alcohol and other compounds.
摘要:
The subject invention provides "no sat" canola oil. The subject invention also provides seeds that can be used to produce such oils. Plants that produce these seeds are also included within the subject invention. All of this was surprisingly achieved by using a delta-9 desaturase gene in canola. This technology can be applied to other plants as disclosed herein. Oils of the subject invention have particularly advantageous characteristics and fatty acid profiles, which were not heretofore attained. The subject invention still further provides a plant-optimized delta-9 desaturase gene. The subject invention still further provides a plant-optimized delta-9 desaturase gene. In some preferred embodiments, a preferred plant comprises at least two copies of a delta-9 desaturase gene of the subject invention. Seeds produced by such plants surprisingly do not exhibit effects of gene silencing but rather have further surprising reductions in levels of total saturates.
摘要:
The present invention discloses anti-malarial compound of formula (I) Formula (I) wherein, X is selected from O or NH; R1, R2, R3, R4 and R5 is selected from H or OMe or CH3, -CH2-O-CH2- or -CH=CH-CH=CH-; Y is selected from O or NH and R6, R7 is selected from the following compounds: or pharmaceutically acceptable salts thereof, process for preparation and a pharmaceutical composition containing the same.
摘要:
The invention is to a process for producing an acrylate product. The process includes the steps of contacting an alkanoic acid and an alkylenating agent over a catalyst composition under conditions effective to produce the acrylate product. The catalyst composition comprises vanadium, bismuth and titanium. Preferably, the catalyst comprises 0.3 wt % to 30 wt % vanadium, 0.1 wt % to 69 wt % bismuth and 0.1 wt % to 61 wt % tungsten, in an active phase.
摘要:
Die Erfindung betrifft Carboxyl-/Carboxylat- und Estergruppen aufweisende Kammpolymere, beinhaltend oder bestehend aus a) 0.1-0.9 Molanteilen einer Teilstruktureinheit S1, die sich ableitet von einer Acryl- / Methacryl- oder Maleinsäureeinheit, b) 0-0.4 Molanteilen einer Teilstruktureinheit S2, die sich beispielsweise ableitet von einer Acryl- / Methacryl- oder Maleinsäureeinheit die mit einem C 1 bis C 20 -Alkanol oder mit einem einseitig-alkylverschlossenen Polyalkylenglykol, bevorzugt einem Polyethylenglykol, verestert ist und c) 0.1-0.4 Molanteile einer Teilstruktureinheit S3, die sich ableitet von einer Acryl- / Methacryl- oder Maleinsäureeinheit die mit einem Polyalkylenglykolmonoalkylether der eine terminale, sekundäre Hydroxylgruppe der Form-CH(R 3 )OH aufweist, verestert ist, wobei R 3 eine sperrige Alkylgruppe, vorzüglich eine Methylgruppe ist. Weiter betrifft die Erfindung ein Herstellverfahren solcher Kammpolymeren, Bindemittelzusammensetzungen enthaltend dieselben und Verwendungen solcher Kammpolymere.
摘要:
Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure:
enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.